Five-year Efficacy and Safety of Tafasitamab in Patients Wit

Five-year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory DLBCL: Final Results From the Phase II L-MIND Study

Expert hematologist-oncologist Grzegorz Nowakowski, MD, reviews data from the 5-year analysis of the L-MIND study combining tafasitamab with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

Related Keywords

Grzegorz Nowakowski , , Five Year Efficacy , Patients With Relapsed , Final Results From , Partnership With , Dlbcl , Diffuse Largeb Cell Lymphoma , B Cell Lymphoma , Lymphoma , L Mind Trial , L Mind Study , Blmind , Tl Mind , Tafasitamab , Cd19 , Anti Cd19 ,